| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10013291 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS10012007 | HBV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30003943 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30009207 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30086264 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30076416 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS30083332 | HIV | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS44001718 | HTLV-1 | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
| TVIS44039289 | HTLV-1 | ENSG00000112038.18 | protein_coding | OPRM1 | No | No | 4988 | B8K2Q5 G8XRH4 G8XRH5 L0E130 P35372 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | OPRM1 |
|---|---|
| DrugBank ID | DB00802 |
| Drug Name | Alfentanil |
| Target ID | BE0000770 |
| UniProt ID | P35372 |
| Regulation Type | agonist |
| PubMed IDs | 10955836; 15694871; 16906017; 11240090; 11752352 |
| Citations | Garrido M, Gubbens-Stibbe J, Tukker E, Cox E, von Frijtag J, Kunzel D, IJzerman A, Danhof M, van der Graaf PH: Pharmacokinetic-pharmacodynamic analysis of the EEG effect of alfentanil in rats following beta-funaltrexamine-induced mu-opioid receptor "knockdown" in vivo. Pharm Res. 2000 Jun;17(6):653-9.@@Lotsch J, Geisslinger G: Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med. 2005 Feb;11(2):82-9.@@Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J: The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics. 2006 Sep;16(9):625-36.@@Leung A, Wallace MS, Ridgeway B, Yaksh T: Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Illicit |
| Direct Classification | Anilides |
| SMILES | CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O |
| Pathways | Alfentanil Action Pathway |
| PharmGKB | PA448084 |
| ChEMBL | CHEMBL634 |
